Blog Band - Page 271 of 299

15

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and…

13

Jul 2021

VIEWPOINTS

PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of…

12

Jul 2021

VIEWPOINTS

PharmaShots Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021

In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination…

08

Jul 2021

TOP 20

Top 20 Innovative Digital Therapeutics Companies of 2020

The digital therapeutics market has unsurprisingly exploded in last few years. Available virtually- digital therapies are developed by engineers- clinicians & scientists and are rigorously tested- making it possible for…

07

Jul 2021

VIEWPOINTS

PharmaShots Interview: NephroSant’s Dr. Minnie Sarwal Shares Insights on QSant and the Need for Precision Medicine in Kidney Health

In an interview with PharmaShots, Dr. Minnie Sarwal, CEO and Co-Founder of NephroSant shares her view on the QSant and how this urine test can improve outcomes for transplant patients. She also…

07

Jul 2021

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2021

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and…

05

Jul 2021

VIEWPOINTS

PharmaShots Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

In an interview with PharmaShots, Myovant's Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences shares his views on the CHMP's positive opinion for Ryeqo (Relugolix Combination Tablet). Shots:…

02

Jul 2021

VIEWPOINTS

PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

In an interview with PharmaShots, Dr. Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School…

30

Jun 2021

VIEWPOINTS

PharmaShots Interview: Repertoire’s Andrea DiFabio Shares Insights on the Importance of Series B Funding

In an interview with PharmaShots, Andrea DiFabio, JD, Chief Legal and Administration Officer of Repertoire Immune Medicines shares her views on the importance of $189M series B funding and how…

30

Jun 2021

INSIGHTS+

Insights+ Key Biosimilars Events of June 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded…

Insights+: The US FDA New Drug Approvals in June 2021

PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

PharmaShots Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021

Top 20 Innovative Digital Therapeutics Companies of 2020

PharmaShots Interview: NephroSant’s Dr. Minnie Sarwal Shares Insights on QSant and the Need for Precision Medicine in Kidney Health

PharmaShots’ Key Highlights of Second Quarter 2021

PharmaShots Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

PharmaShots Interview: Repertoire’s Andrea DiFabio Shares Insights on the Importance of Series B Funding

Insights+ Key Biosimilars Events of June 2021

Contact US

OUR INFORMATION

FOLLOW US